Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Dyanet Alvarez

Neurology South Miami, FL Medical Doctor

NPI 1083241020 CMS profile 11558804

7000 Sw 62Nd Ave Ste 300, South Miami, FL 33143

Open in the dashboard

General payments

$1,301

52 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dyanet Alvarez of South Miami, FL is reported in the CMS Open Payments database as having received $1,301 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,169 47
2024 General $48 2
2023 General $83 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dyanet Alvarez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Dyanet Alvarez were reported at $1,169. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Dyanet Alvarez Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $83 $464 $119–$2,312 $160
2024 $48 $468 $119–$2,323 $164
2025 $1,169 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $284 15 payments
  2. UCB, Inc. $150 3 payments
  3. TG Therapeutics, Inc. $128 3 payments
  4. Lilly USA, LLC $87 3 payments
  5. Jazz Pharmaceuticals Inc. $81 3 payments
  6. AstraZeneca Pharmaceuticals LP $77 3 payments
  7. Merz Pharmaceuticals, LLC $68 4 payments
  8. Eisai Inc. $58 3 payments
  9. Argenx US, Inc. $55 2 payments
  10. Neurocrine Biosciences, Inc. $54 2 payments
  11. Other $258 11 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,283 51 payments
  2. Education $18 1 payment
Products named General payments · program years 2023–2025
  1. BRIUMVI $128 3 payments
  2. BOTOX $115 4 payments
  3. Briviact $100 2 payments
  4. VYALEV $90 4 payments
  5. KISUNLA $87 3 payments
  6. Epidiolex $81 3 payments
  7. WAINUA $77 3 payments
  8. INBRIJA $68 4 payments
  9. Xeomin $68 4 payments
  10. Leqembi $58 3 payments
  11. Other $455 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record